The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer
The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.
EP: 1.An Overview of HR+, HER2- Metastatic Breast Cancer
EP: 2.Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer
EP: 3.The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer
EP: 4.Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy
EP: 5.CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer
Now Viewing
EP: 6.The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer
EP: 7.The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
EP: 8.Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer
EP: 9.Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer
Related Videos
Related Content
